Le Lézard
Classified in: Health
Subjects: CCA, FVT

Encompass Health announces date of 2024 first quarter earnings call


BIRMINGHAM, Ala., April 10, 2024 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced it will report results for its first quarter ended March 31, 2024, after the market closes Wednesday, April 24, 2024. The Company will host an investor conference call at 10 a.m. ET on April 25, 2024, to discuss its results.

The conference call may be accessed by dialing 800-579-2543 and giving the conference ID EHCQ124. International callers should dial 785-424-1699 and give the same conference ID. Please call approximately 10 minutes before the start of the call to ensure you are connected.

A live webcast of the conference call and an online replay of the conference call can be found on the Company's investor website at https://investor.encompasshealth.com.

About Encompass Health
Encompass Health (NYSE: EHC) is the largest owner and operator of rehabilitation hospitals in the United States. With a national footprint that includes 160 hospitals in 37 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's World's Most Admired Companies and Modern Healthcare's Best Places to Work in Healthcare. For more information, visit encompasshealth.com, or follow us on our newsroom, Twitter, Instagram and Facebook.

Media contact:
Kennedi Spurling | 205-970-5912
[email protected]

Investor Relations contact:
Mark Miller | 205-970-5860
[email protected]

SOURCE Encompass Health Corp.


These press releases may also interest you

at 00:01
New Findings: Child Care Prices Continue to Rise as Supply Remains Stagnant
America's child care supply remains flat, while child care prices continue to increase, according to a new report released today by Child Care Aware® of America (CCAoA) that highlights the burden families face accessing quality and affordable child...

at 00:01
Deloitte's 2024 Gen Z and Millennial Survey finds these generations stay true to their values as they navigate a rapidly changing world
The cost of living is Gen Zs' and millennials' top societal concern, but green shoots of optimism for the economy and their personal finances are emergingNearly nine in 10 Gen Zs and millennials say purpose is important to their job satisfaction and...

at 00:00
AmacaThera doses First In Human Study to Evaluate, AMT-143, for Non-opioid Treatment of Post-operative Pain
AmacaThera Inc, a clinical stage biotechnology company specializing in the development of advanced sustained release hydrogel formulations, has dosed its first human subject with AMT-143, the company's lead asset in non-opioid acute pain management. ...

14 mai 2024
Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 - March 2025)
BioArctic AB's (publ) partner Eisai today said that they expect Leqembi sales to total JPY 56.5 billion (approximately SEK 4 billion) for their fiscal year (FY) 2024 (April 2024 through March 2025). This would generate approximately SEK 360 M in net...

14 mai 2024
Flow Cytometry Market size is set to grow by USD 6038.44 million from 2023-2027, increasing expenditure on r and d to boost the market growth, Technavio
The global flow cytometry market  size is estimated to grow by USD 6038.44 million from 2023-2027, according to Technavio. The market is estimated to grow at a CAGR of about 13.12%  during the forecast period....

14 mai 2024
Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for subcutaneous maintenance dosing
BioArctic AB's (publ) partner Eisai announced today that they have initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: Leqembi) subcutaneous...

More news about Health...


News published on and distributed by: